Condensed Consolidated Interim Financial Statements of

HAPBEE TECHNOLOGIES, INC.

For the three and nine months ended September 30, 2025 and 2024 (Expressed in U.S. dollars)

(Unaudited)

HAPBEE TECHNOLOGIES, INC.

Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2025 and 2024

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated interim financial statements of Hapbee Technologies, Inc. for the three and nine months ended September 30, 2025 and 2024 have been prepared by the management of the Company and approved by the Company's Audit Committee and the Company's Board of Directors.

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indication that an auditor has not reviewed the condensed consolidated interim financial statements.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed consolidated interim financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of the condensed consolidated interim financial statements by an entity's auditor.

Hapbee Technologies, Inc. Condensed Consolidated Interim Statement of Financial Position for the three and nine months ended September 30, 2025 and 2024

Expressed in U.S. dollars	Sep 30, 2025 (Unaudited)	Dec 31, 2024 (Audited)
	\$	\$
Assets		
Current assets		
Cash	259,791	132,274
Receivables	218,418	251,175
Inventory (note 4)	243,431	264,891
Prepaid expenses	626,235	381,645
Total current assets	1,347,875	1,029,985
Non-current assets		
Intangible assets (note 5)	1,680,354	1,196,750
Total non-current assets	1,680,354	1,196,750
Tr. ()	2 020 220	2 22 (52 5
Total assets	3,028,229	2,226,735
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities (note 6)	1,716,087	2,890,607
Product warranty liability (note 7)	9,130	9,130
Loans Payable	280,065	63,764
Unearned revenue (note 8)	167,774	139,591
Total current liabilities	2,173,056	3,103,092
Non-current liabilities		
Warrant liability (note 12)	1,169,836	1,583,842
Promissory Notes (note 14)	351,335	1,499,577
Convertible debentures (note 15)	161,217	161,217
Total non-current liabilities	1,682,388	1,196,750
Total liabilities	3,855,444	6,347,728
E author		
Equity Shore conital (note 0)	21 640 452	10 505 749
Share capital (note 9) Reserves	21,640,452 6,682,628	19,595,748 6,702,863
Retained earnings, beginning	(30,419,604)	(23,823,493)
Net Income (loss) for the period	1,269,309	(6,596,111)
Total shareholders' equity	(827,215)	(4,120,993)
• •		
Total liabilities and equity	3,028,229	2,226,735

Nature of operations and going concern (note 1)

Basis of presentation (note 2)

Commitments and contingencies (note 18)

Approved on behalf of the Board of Directors on November 28, 2025.

"Michael Matysik" "Rizwan Shah" Director Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Hapbee Technologies, Inc. Condensed Consolidated Interim Statement of Comprehensive Income for the three and nine months ended September 30, 2025 and 2024

	Three month	s ended	Nine months ended		
Expressed in U.S. dollars	Sep 30, 2025	Sep 30, 2024	Sep 30, 2025	Sep 30 2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	\$	\$	\$	\$	
Revenues					
Sales product and service	446,897	151,196	1,381,257	476,873	
Royalties	, -	-	(8,495)	-	
Costs of good sold	(252,137)	(43,307)	(665,848)	(115,071)	
Gross Profit	194,760	107,889	706,914	361,802	
Gross Margin	44%	71%	51%	76%	
Expenses					
Amortization of Intangible Assets (note 5)	19,125	52,874	57,375	158,623	
Consulting (note 14)	(1,427,007)	561,558	(1,097,105)	1,645,965	
Marketing, Advertising and promotion	36,838	115,630	211,132	128,281	
General and administrative	111,992	208,946	442,294	457,701	
Product development costs	347,770	144,486	767,926	277,381	
Capitalized Development	(249,000)	-	(528,599)	-	
Professional fees	50,705	103,641	108,361	163,690	
Salaries and wages (note 14)	(127,230)	19,146	(109,773)	37,191	
Share-based compensation (note 10)	· · · · · · · · · · · · · · · · · · ·	-	-	69,492	
Total operating expenses	(1,236,807)	1,206,281	(148,389)	2,938,324	
Operating profit/(loss) before other item	1,431,567	(1,098,392)	855,303	(2,576,522)	
Other item:					
Change in fair value of warrants liability (note 12)	-	(131,940)	414,006	(1,048,547)	
Net Profit/(loss) for the period	1,431,567	(1,230,332)	1,269,309	(3,625,069)	

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Hapbee Technologies, Inc. Condensed Consolidated Interim Statement of Changes in Equity for the nine months ended September 30, 2025 and 2024

Expressed in U.S. dollars

	Number of subordinated voting shares	Value subordinated voting shares \$	Number multiple voting shares	Value multiple voting shares \$	Accumulated other comprehensive income	Reserves \$	Deficit \$	Total \$
Balance, Jan 1, 2024	115,368,547	15,219,403	450,000	39	-	6,392,054	(23,822,477)	(2,210,981)
Issuance of shares for non-brokered private placement	73,148,297	4,055,351	-	-	-	-	-	4,055,351
Share issuance cost	-	(98,673)	-	-	-	-	-	(98,673)
Share-based compensation	2,671,250	26,173	-	-	-	43,319	-	69,492
Net loss and comprehensive loss for the period	-	-	-	-	-	-	(3,625,069)	(3,625,069)
Balance, Sep 30, 2024	191,188,094	19,202,254	450,000	39	-	6,435,373	(27,447,546)	(1,809,880)
Balance, Jan 1, 2025	198,105,583	19,595,709	450,000	39	-	6,702,863	(30,419,604)	(4,120,993)
Net income for the nine month period	<u>-</u>	-	-	-	-	-	1,269,309	1,269,309
Issuance of shares for transaction	25,570,000	2,044,704	-	-	-	-	-	2,044,704
Share-based compensation	2,023,500	-	-	-	-	(20,235)	-	(20,235)
Balance, Sep 30, 2025	225,699,083	21,640,413	450,000	39	-	6,682,628	(29,150,295)	(827,215)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Hapbee Technologies, Inc. Condensed Consolidated Interim Statement of Cash Flows for the three and nine months ended September 30, 2025 and 2024

	Three months ended		Nine months ended		
Expressed in U.S. dollars	Sep 30, 2025	Sep 30, 2024	Sep 30, 2025	Sep 30, 2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	\$	\$	\$	\$	
Operating activities					
Net Profit (loss) for the period	1,431,567	(1,230,332)	1,269,309	(3,625,069)	
Item not involving cash:					
Amortization of intangible assets	19,125	52,874	57,375	158,623	
Change in warrant liability – private placement	-	304,443	-	1,320,282	
Change in warrant liability – fair value	-	(172,503)	(414,006)	(271,735)	
Changes in non-cash working capital balances:					
Decrease / (increase) in receivables	(19,085)	(10,158)	(87,600)	(45,339)	
Decrease / (increase) in prepaid expenses	(206,145)	-	(403,350)	-	
Decrease / (increase) in inventory	(7,690)	(87,727)	180,220	(599,917)	
Decrease/ (increase) in accounts payable and accrued liabilities	(852,406)	9,790	(1,054,164)	25,765	
(Decrease) / increase in loans payable	(697,350)	(18,419)	216,302	(101,579)	
(Decrease) / increase in unearned revenue	59,710	(22,034)	28,183	(66,102)	
Net cash used in operating activities	(272,274)	(1,174,066)	(207,731)	(3,205,071)	
Investing activities					
Development costs incurred	(249,000)	-	(540,979)	-	
Net cash used in investing activities	(249,000)		(540,979)		
Financing activities					
Proceeds from subordinated voting shares issuance	1,535,081	2,000,000	2,044,704	4,055,556	
Reduction in reserves	-	_,, -	(20,235)	-	
Reduction in promissory notes	(914,969)	-	(1,148,242)	-	
Share issuance cost	-	-	-	(61,018)	
Proceeds from convertible debentures issuances	-	-	_	189,281	
Net cash provided by financing activities	620,112	2,000,000	876,227	4,244,837	
Effect of foreign exchange	-	(50,018)	-	32,632	
Increase (decrease) in cash during the period	98,838	775,916	127,517	1,011,380	
Cash, beginning of the period	160,953	448,117	132,274	212,653	
Cash, end of the period	259,791	1,224,033	259,791	1,224,033	

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

1. NATURE OF OPERATIONS AND GOING CONCERN

Hapbee Technologies, Inc. (formerly known as Elevation Technologies, Inc.) (the "Company") is a company incorporated on January 3, 2019 under the Business Corporations Act (British Columbia). Its registered and record office and corporate office is located at 700 West Georgia Street, Suite 2500, Vancouver, BC V7Y 1B3. The Company's principal business activity is to commercialize consumer digital products that will deliver one or more ultra-low radio frequency energy signals to produce mood-altering effects. On June 15, 2020, the Company completed a forward stock split of its common shares on a 1 for 4.5 basis. The Company had 13,455,000 common shares issued and outstanding and the resulting post stock split common shares outstanding were 60,547,500. The numbers of common shares issuable pursuant to all share capital have been retrospectively adjusted in accordance with the stock split ratio. On the same day, the Company amended its articles in order to change its authorized capital from an unlimited number of common shares, without par value, to an unlimited number of Subordinated Voting Shares, and created a new class of unlimited number of Multiple Voting Shares, all without par value. On June 16, 2020, the Company completed an amalgamation with Zander Capital Ltd. ("Zander"), refer to the Company's financial statements for the vear ended December 31, 2022 for details.

The Company's operations have been financed through the sale of Subordinated Voting Shares, Multiple Voting Shares and issuance of debt. The Company has incurred a significant operating loss since inception and has an accumulated deficit of \$ 29,150,295 as of September 30, 2025.

These condensed consolidated financial statements have been prepared on a going-concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due. For the three month period ended September 30, 2025, the Company incurred a net profit of \$1,431,567.

The Company's ability to continue as a going concern is dependent upon its ability to fund its working capital and operating requirements and eventually to generate positive cash flows from operations. These condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported revenues and expenses and statement of financial position classifications that would be necessary were the going concern assumption determined to be inappropriate and these adjustments could be material.

2. BASIS OF PRESENTATION

a) Statement of Compliance

These condensed consolidated interim financial statements, including comparatives, have been prepared using accounting policies consistent with International Financial Reporting Standards ("IFRS") and in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting. These condensed consolidated interim financial statements should be read in conjunction with the Company's financial statements for the year ended December 31, 2024.

These unaudited condensed consolidated interim financial statements are expressed in US dollars and have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting on a going concern basis. The accounting policies set out below have been applied consistently to all periods presented in these condensed consolidated interim financial statements as if the policies have always been in effect.

b) Basis of Preparation

These financial statements have been prepared on a historical cost basis, except for certain financial instruments measured at fair value through profit or loss, which are stated at their fair value. In addition, these financial statements have been prepared using the accrual basis of accounting, except for certain cash flow information. The financial statements, unless otherwise specified, are presented in US dollars, which is the functional currency of the Company.

c) Functional and presentation currency

These condensed consolidated interim financial statements are presented in US dollars, unless otherwise noted.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

d) Basis of consolidation

These condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the condensed consolidated financial statements.

e) Approval of the Financial Statements

The condensed consolidated financial statements of the Company for the period ended September 30, 2025, were approved and authorized for issue by the Board of Directors on November 28, 2025.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these condensed consolidated financial statements.

a) Critical accounting judgments and estimates

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results could differ from these estimates. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about critical accounting judgments and estimates in applying accounting policies that have the most significant impact on the amounts recognized in the consolidated financial statements are outlined below.

Share-based payments and warrant liability

The Company makes certain estimates and assumptions when calculating the estimated fair values of stock options granted and warrants issued. The significant assumptions used include estimates of expected volatility, expected life, expected dividend rate and expected risk-free rate of return. Changes in these assumptions may result in a material change to the expense recorded for grants of stock options and the issuance of warrants. Certain warrants issued during the year ended December 31, 2024 are accounted for as derivative liabilities (see Note 12).

Deferred income taxes

The Company is periodically required to estimate the tax base of assets and liabilities. Where applicable tax laws and regulations are either unclear or subject to varying interpretations, it is possible that changes in these estimates could occur that materially affect the amounts of deferred income tax assets and liabilities recorded in the consolidated financial statements. Changes in deferred tax assets and liabilities generally have a direct impact on earnings in the period of changes.

Each period, the Company evaluates the likelihood of whether some portion or all of each deferred tax asset will not be realized. This evaluation is based on historic and future expected levels of taxable income, the pattern and timing of reversals of taxable temporary timing differences that give rise to deferred tax liabilities, and tax planning initiatives. Levels of future taxable income are affected by, among other things, the market price for commodities, production costs, quantities of proven and probable reserves, interest rates, and foreign currency exchange rates.

Going concern

The determination of the Company's ability to continue as a going concern requires the Company to make certain judgements about whether the Company will be able to realize its assets and discharge its liabilities in the normal course of business.

Intangible assets

Management is required to use judgement in determining the useful economic lives of identifiable intangible assets and the capitalization of costs for internally generated intangible assets is subject to judgment including the technical feasibility, timeframe to commercialization, assessment of availability of resources to complete the project, and if economic benefits will be generated form its use. Management is required to use judgement in determining the useful economic lives of identifiable intangible assets. Judgement is also required in identifying indicators of impairment of the Company's intangible assets.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

At each financial position reporting date, the carrying amounts of the Company's intangible assets, are reviewed to determine whether there is any indication that those assets are impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash generating unit to which the asset belongs. This requires management to make certain estimates and judgements which could be materiality different than actual results.

Revenue recognition

The Company's revenue is comprised of sales of its products which consists of its wearable device and annual/monthly subscription. As a result, the Company is required to allocate the transaction prices amongst the multiple elements of its packaged products. This requires that management make judgements and estimates related to the allocation which are subjective and could result in material differences if changed.

b) Financial Instruments

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of a financial instrument. Financial assets and financial liabilities are initially measured at fair value. Financial assets are classified into one of the following specified categories: amortized cost, fair value through profit or loss ("FVTPL") or fair value through other comprehensive income ("FVOCI"). Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities classified as FVTPL) are added to, or deducted from, the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified as FVTPL are recognized immediately in the statement of loss and comprehensive loss.

The Company's financial instruments are classified as follows:

Financial instrument	Measurement
Cash	FVTPL
Receivables	Amortized cost
Accounts payable	Amortized cost
Unearned revenue	Amortized cost
Prepaid Expenses	Amortized cost
Loans	Amortized cost
Notes	Amortized cost
Debentures	Amortized cost

Financial Assets

Subsequent to initial recognition, financial assets classified and measured at amortized cost using the effective interest method.

Financial assets classified as FVTPL are recognized initially at fair values less transaction costs and are subsequently carried at fair value, with changes in the fair value recorded in comprehensive income. The fair value measurements are based on level 1 input, being quoted prices in active markets for identical instruments.

c) Impairment of financial assets at amortized cost

The Company recognizes an allowance using the expected credit losses ("ECL") model on financial assets classified as amortized cost. The Company has elected to use the simplified approach for measuring ECL by using a lifetime expected loss allowance for all accounts receivable. Under this model, impairment provisions are based on credit risk characteristics and days past due. When there is no reasonable expectation of collection, financial assets classified as amortized cost are written off. Indications of credit risk arise based on failure to pay and other factors. Should objective events occur after an impairment loss is recognized, a reversal of impairment is recognized in the statement of loss and comprehensive loss.

Financial Liabilities

Financial liabilities are classified as and are measured at amortized cost subsequent to initial measurement at fair value.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

Offsetting financial instruments

Financial assets and financial liabilities are offset and the net amount reported on the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously.

d) Cash

Cash is comprised of cash held in current operating bank accounts.

e) Inventory

Inventory includes products held for resale in the ordinary course of business (finished goods) and is measured at the lower of cost and net realizable value. The cost of inventory is determined generally on a first-in and first-out basis.

f) Revenue recognition

The Company's revenues are derived from both the sale of hardware as well as subscriptions fees related to the use of its products.

Sales of hardware is recognized upon the transfer of control of the promised product to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products.

Subscription fees are comprised of fees that provide customers with access to its software and application over the contract term without taking possession of the software. Revenue from subscription fees are recognized over the term of the contract.

The Company also collects advance payments from its customers which are recorded as unearned revenue. Recognition of the unearned revenue for subscription fees is over the term of the contract. For sale of hardware, recognition of unearned revenue is based on control of products transferring to customers.

g) Research and development expenditures

Research expenditures are recorded in the period incurred. Product development expenditures are expensed in the period incurred unless the product candidate meets specific criteria related to technical, market and financial feasibility for deferral and amortization. The Company's policy is to amortize deferred product development expenditures over the expected future life of the product once product revenues are recorded. The future life of the product is estimated to be 8 years.

h) Share-based payments

The Company has a share-based compensation plan. Awards of options under this plan are expensed or recorded as additions to resource properties based on the estimated fair value of the options at the grant date, with a corresponding credit to contributed surplus in shareholders' equity. Fair value is estimated using the Black-Scholes pricing model. If the options are subject to a vesting period, the estimated fair value is recognized over this period on a graded vesting basis, based on the Company's estimate of the shares that will eventually vest.

Equity-settled share-based payment transactions with parties other than employees and those providing similar services are measured at the fair value of the goods or services received, except where that fair value cannot be estimated reliably, in which case they are measured at the estimated fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty renders the service.

Cash consideration received on exercise of options is credited to share capital together with the amounts originally recorded as share-based compensation related to the exercised options.

i) Income taxes

Current income taxes

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities based on taxable income for the year. The tax rates and tax laws used to compute the amount are those that are enacted, or substantively enacted, at the reporting date in the countries where the Company operates and generates taxable income.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

Income tax is recognized in the statements of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity. Current income tax relating to items recognized directly in equity is recognized in the statements of changes in equity and not in the statements of loss and comprehensive loss.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense.

Deferred income taxes

Deferred income taxes are calculated using the liability method on temporary differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognized for all taxable temporary differences, except:

- when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognized for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses, can be utilized.

Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted, or substantively enacted, at the reporting date. Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Deferred tax relating to items recognized outside of profit or loss is recognized outside of profit or loss. Deferred tax items are recognized in correlation to the underlying transaction either in other comprehensive loss or directly in equity.

j) Loss per share

Loss per share is calculated based on the weighted average number of shares outstanding during the year. The Company follows the treasury method of calculating diluted earnings per share. This method assumes that any proceeds from the exercise of stock options and other dilutive instruments would be used to purchase common shares at the average market price during the year. Diluted loss per share is equal to loss per share since the exercise of all options and warrants is anti-dilutive.

k) Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are measured at management's best estimate of the expenditure required to settle the obligation at the end of the reporting period and are discounted to present value where the effect is material. There were no material provisions recorded within the condensed consolidated interim financial statements as of September 30, 2025.

1) Related party transactions

Unless otherwise disclosed herein, all transactions with related parties are in the normal course of business and are measured at the exchange amount (note 13).

m) Intangible assets - Licenses

Upon acquisition, intangible assets with finite useful lives are recorded at fair value and are carried at cost less accumulated amortization and impairment losses. Amortization is calculated over the cost of the asset, or revalued amount, less its residual

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

value. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives of the Company's licenses are 20 years.

n) Intangible assets - Development costs

Development expenditures can be capitalized only where a development project meets certain conditions, including technical feasibility of the intangible asset, intention to complete the project, ability to sell the intangible asset, probability that the intangible asset can produce future economic benefits, availability of resources to complete the project, and ability to reliably measure the expenditure attributable to the intangible asset. Development projects are reviewed as they arise and on an ongoing basis to assess whether all the conditions have been met. Amortization is calculated over the cost of the asset, or revalued amount, less its residual value. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset.

o) Adoption of new pronouncements

A number of amendments to standards and interpretations applicable to the Company are not yet effective for the period ended September 30, 2025, and have not been applied in preparing these consolidated financial statements nor does the Company expect these amendments to have a significant effect on its consolidated financial statements.

4. INVENTORY

	Sep 30, 2025	Dec 31, 2024
	\$	\$
Finished goods	91,673	151,200
Components and manufacturing materials	151,758	113,691
	243,431	264,891

5. INTANGIBLE ASSETS

The Company capitalized the acquisition costs of licenses and development costs related to the design and development of the device prototype.

a) Licenses

License Agreement for Certain Sensory Technologies

On March 29, 2019, the Company acquired a license from EMulate Therapeutics Inc. ("EMulate"). The Company paid an upfront fee of USD \$1,500,000 for this license. The Company will pay EMulate, on a quarterly basis, 20% royalties on the net income from sales, lease or rental of the authorized product containing cognate signals. The royalty rate on the first USD \$10,000,000 will be 20%. In exchange, the Company will obtain from EMulate certain exclusive rights and licenses to develop, use, import, and commercialize consumer digital products using EMulate's technology. The license has a term of 20 years from the effective date.

Pursuant to amendments to the License Agreement with Emulate, the effective date of the License Agreement was changed to October 26, 2020. All other terms remain unchanged.

License Agreement for Certain Sensory Technologies

On October 30, 2019, the Company acquired another license from EMulate. The Company paid an upfront fee of USD \$30,000 for this license. The Company will pay EMulate, on a quarterly basis, 20% royalties on the net income from sales, lease or

rental of the authorized product containing cognate signals. The royalty rate on the first USD \$10,000,000 will be 20%. In exchange, the Company will obtain from EMulate certain exclusive rights and licenses to develop, use, import, and commercialize consumer digital products using EMulate's technology. The license has a term of 20 years from the effective date.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

Pursuant to amendments to the License Agreement with Emulate, the effective date of the License Agreement was changed to October 26, 2020. All other terms remain unchanged.

On April 21, 2021, the Company acquired another license from EMulate. The Company paid an up-front fee of USD \$10,000 for this license. The Company will pay EMulate, on a quarterly basis, 20% royalties on the net income from sales, lease or rental of the authorized product containing cognate bedtime signals. The royalty rate on the first USD \$10,000,000 will be 20%. In exchange, the Company will obtain from EMulate certain exclusive rights and licenses to develop, use, import, and commercialize consumer digital products using EMulate's technology. The license has a term of 20 years from the effective date of April 21, 2021.

On July 29, 2021, the Company acquired another license from EMulate. The Company paid an up-front fee of USD \$10,000 for this license. The Company will pay EMulate, on a quarterly basis, 20% royalties on the net income from sales, lease or rental of the authorized product containing cognate bedtime signals. The royalty rate on the first USD \$10,000,000 will be 20%. In exchange, the Company will obtain from EMulate certain exclusive rights and licenses to develop, use, import, and commercialize consumer digital products using EMulate's technology. The license has a term of 20 years from the effective date of July 29, 2021.

Sensory technologies include the human senses of happiness, sleepiness, focus, alertness, calmness and relaxation.

b) Development Costs—During the three months ended September 30, 2025, the Company incurred development costs of \$347,770 out of which \$249,000 was capitalized related to the development of an augmentative wearable device that emulates normal molecular interactions in the body through small, specific magnetic fields. Past costs have met the criteria for capitalization under IAS 38.

The following table outlines Hapbee's intangible assets as of September 30, 2025:

	Sep 30, 2025	Dec 31, 2024
	1.500.000	1.700.000
License Agreement for certain sensory technologies	1,500,000	1,500,000
License Agreement for certain sensory technologies	30,000	30,000
License Agreement for certain sensory technologies	20,000	20,000
Development costs capitalized	540,979	1,079,980
Development cost-Impairment expense	-	(449,993)
Accumulated amortization of intangible assets:		
- license fees	(410,625)	(353,250)
- development costs	-	(629,987)
av otephical costs	1,680,354	1,196,750
6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	San 20, 2025	Dog 21, 2024
	Sep 30, 2025	Dec 31, 2024
T 1 1 1 11 11 11 11 11 11 11 11 11 11 11	1.716.007	1 405 272
Trade accounts payable and accrued liabilities	1,716,087	1,495,372
Amounts payable to related parties (note 13)		1,395,235
	1,716,087	2,890,607
7. PRODUCT WARRANTY LIABILITY		
	Sep 30, 2025	Dec 31, 2024
	\$	\$
Product warranty liability	9,130	9,130
•		,
	9,130	9,130

Hapbee Technologies, Inc. Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

8. UNEARNED REVENUE

	Sep 30, 2025	Dec 31, 2024
	\$	\$
Unearned revenue	167,774	139,591
	167,774	139,591

The Company records unearned revenue pertaining to the unearned portions of the subscriptions collected from customers.

9. SHARE CAPITAL

On June 15, 2020, the Company amended its articles in order to change its authorized capital from an unlimited number of common shares, without par value, to an unlimited number of Subordinated Voting Shares, and created a new class of unlimited number of Multiple Voting Shares, all without par value.

Authorized

The Company's authorized capital consists of (i) an unlimited number of Subordinated Voting Shares, and (ii) an unlimited number of Multiple Voting Shares. The holders of Subordinated Voting Shares are entitled to one vote for each Subordinated Voting share held. The holders of Multiple Voting Shares are entitled to 100 votes for each Multiple Voting Share held.

Voting Rights

All holders of Subordinated Voting Shares and Multiple Voting Shares are entitled to receive notice of any meeting of shareholders of the Company, and to attend, vote and speak at such meetings, except those meetings at which only holders of a specific class of shares are entitled to vote separately as a class under the Business Corporations Act (British Columbia). A quorum for the transaction of business at any meeting of shareholders is two persons present at the meeting, each of whom is entitled to vote at the meeting, and who hold or represent by proxy in the aggregate not less than 5% of the outstanding shares of the Company entitled to vote at the meeting.

On all matters upon which shareholders the Company are entitled to vote:

Each Subordinated Voting Share is entitled to one vote per Subordinated Voting Share; and each Multiple Voting Share is entitled to 100 votes per Multiple Voting Share.

Unless a different majority is required by law or the articles of the Company, resolutions to be approved by shareholders require approval by a simple majority of shareholders.

Conversion Rights and Conditions

The issued and outstanding Multiple Voting Shares, including fractions thereof, may at any time, subject to the FPI Condition (as defined below), at the option of the holder, be converted into Subordinated Voting Shares at a ratio of 100 Subordinated Voting Shares per Multiple Voting Share. Further, the board of directors of the Company may determine in the future that it is no longer advisable to maintain the Multiple Voting Shares as a separate class of shares and may cause all of the issued and outstanding Multiple Voting Shares to be converted into Subordinated Voting Shares at a ratio of 100 Subordinated Voting Shares per Multiple Voting Share. The right of the Multiple Voting Shares to convert into Subordinated Voting Shares is subject

to certain conditions in order to maintain the status of the Company as a "foreign private issuer" under United States securities laws (the "FPI Condition").

At September 30, 2025, the Company has 225,699,083 Subordinated Voting Shares issued and outstanding and 450,000 Multiple Voting Shares issued and outstanding.

Hapbee Technologies, Inc. Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

Shares Issuance

Fiscal Year 2023

- During the year-ended December 31, 2023, the Company issued a total 13,093,488 Subordinated Voting Shares of the Company for total proceeds of \$834,462 (C\$1,126,524).
- On June 12, 2023, the Company closed a non-brokered private placement of 7,904,450 units at \$C0.09 per unit for total proceeds of \$526,963 (\$C711,400). Each unit consisted of one subordinate voting share and one subordinate voting share purchase warrant, and each warrant entitles the holder thereof to purchase one additional subordinate voting share of the Company at a price of \$C0.15 per share for a period of 24 months from the closing date. The Company may, in its sole discretion, provide notice to warrant holders to shorten the warrant expiry date to 60 days from the notice date if the daily volume weighted average closing price of the Company's subordinate voting share is greater than \$C0.50 for the 10 consecutive trading days preceding the notice date. In connection with the private placement, the Company paid no finders' fees. As the warrants are exercisable in a currency different than the Company's functional currency, a resulting derivative exists and the Company allocated the fair value of those warrants as a warrant liability.
- On October 19, 2023, the Company closed a non-brokered private placement of 3,788,587 units at \$C0.08 per unit for total proceeds of \$224,510 (\$C303,088). Each unit consisted of one subordinate voting share and one subordinate voting share purchase warrant, and each warrant entitles the holder thereof to purchase one additional subordinate voting share of the Company at a price of \$C0.15 per share for a period of 24 months from the closing date. The Company may, in its sole discretion, provide notice to warrant holders to shorten the warrant expiry date to 60 days from the notice date if the daily volume weighted average closing price of the Company's subordinate voting share is greater than \$C0.50 for the 10 consecutive trading days preceding the notice date. In connection with the private placement, the Company paid no finders' fees. As the warrants are exercisable in a currency different than the Company's functional currency, a resulting derivative exists and the Company allocated the fair value of those warrants as a warrant liability.
- On December 22, 2023, the Company closed a non-brokered private placement of 1,400,451 units at \$C0.08 per unit for total proceeds of \$82,990 (\$C112,036). Each unit consisted of one subordinate voting share and one subordinate voting share purchase warrant, and each warrant entitles the holder thereof to purchase one additional subordinate voting share of the Company at a price of \$C0.15 per share for a period of 24 months from the closing date. The Company may, in its sole discretion, provide notice to warrant holders to shorten the warrant expiry date to 60 days from the notice date if the daily volume weighted average closing price of the Company's subordinate voting share is greater than \$C0.50 for the 10 consecutive trading days preceding the notice date. In connection with the private placement, the Company paid no finders' fees. As the warrants are exercisable in a currency different than the Company's functional currency, a resulting derivative exists and the Company allocated the fair value of those warrants as a warrant liability.

Fiscal Year 2024

- On April 18, 2024, the Company closed a non-brokered private placement of 50,454,544 units at \$C0.055 per unit for total proceeds of \$2,055,351 (\$C2,775,000). Each unit consisted of one subordinate voting share and one subordinate voting share purchase warrant, and each warrant entitles the holder thereof to purchase one additional subordinate voting share of the Company at a price of \$C0.15 per share for a period of 24 months from the closing date. The Company may, in its sole discretion, provide notice to warrant holders to shorten the warrant expiry date to 60 days from the notice date if the daily volume weighted average closing price of the Company's subordinate voting share is greater than \$C0.50 for the 10 consecutive trading days preceding the notice date. In connection with the private placement, the Company paid no finders'
 - fees. As the warrants are exercisable in a currency different than the Company's functional currency, a resulting derivative exists and the Company allocated the fair value of those warrants as a warrant liability.
- On July 26, 2024, the Company closed a non-brokered private placement of 22,693,753 units at \$C0.12 per unit for total proceeds of \$2,000,000 (\$C2,710,000). Each unit consisted of one subordinate voting share and one half subordinate voting share purchase warrant, and each warrant entitles the holder thereof to purchase one additional subordinate voting share of

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

the Company at a price of \$C0.20 per share for a period of 24 months from the closing date. The Company may, in its sole discretion, provide notice to warrant holders to shorten the warrant expiry date to 60 days from the notice date if the daily volume weighted average closing price of the Company's subordinate voting share is greater than \$C0.50 for the 10 consecutive trading days preceding the notice date. In connection with the private placement, the Company paid no finders' fees. As the warrants are exercisable in a currency different than the Company's functional currency, a resulting derivative exists and the Company allocated the fair value of those warrants as a warrant liability.

- The Company, during the year, issued 6,917,489 subordinate voting shares in exchange for consulting services to suppliers Company in exchange for fees for the sum of \$310,760.
- The Company, during the year received conversion calls on 5,672,000 Restricted Stock Units which were converted into subordinate voting shares, of which Related parties received 4,372,000 subordinate voting shares.

Fiscal Year 2025

The Company during the month of January 2025 converted \$489,388 of accrued payables being license fees to a Related Party, Emulate Inc, in exchange for 10,500,000 subordinated voting shares.

In January 2025, Directors, Management and Consultants to the Company converted 2,023,500 Restricted Share Units (RSU) that vested into Subordinated Voting Shares (SVS) of which 1,923,500 were issued to Related Parties.

During Q3 2025, an additional of 15,070,000 subordinated voting shares were issued at a total consideration of \$1,555,316.

10. STOCK OPTIONS AND RESTRICTED SHARE UNITS

Stock Options

The Company has adopted a stock option plan on November 6, 2019, providing the Board of Directors with the discretion to issue an equivalent number of options of up to 7,515,000 Subordinated Voting Shares of the Company. Stock options are granted with an exercise price of not less than the closing share price the date preceding the date of grant. The details of outstanding items are as follows:

Options granted on October 15, 2022

District 11	00/
Dividend yield	0%
Risk-free interest rate	3.79%
Estimated volatility	110%
Expected life in years	7
Fair value at grant date	\$0.07

On October 15, 2022, the Company granted 3,375,000 incentive stock options to officers, directors and consultants of the Company pursuant to the Company's Plan. The options will be vested 1/3 on the 12, 24 and 36 months' anniversary. The options are all exercisable at the price of \$0.05 (C\$0.07) per share until October 15, 2029, subject to earlier termination in accordance with the Plan.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

The stock options outstanding and exercisable as of September 30, 2025 is as follows:

	Expiry Date	Number of options	Exercise price (\$)
Outstanding at December 31, 2023		8,930,000	0.32
Exercisable at December 31, 2023		6,680,000	0.32
Expired		-	N/A
Granted		-	N/A
Outstanding at 31 December, 2024		8,605,000	0.32
Vested		1,125,000	
Exercisable at December 31, 2024		7,805,000	0.32
Exercisable at September 30, 2025		7,805,000	0.32

The number of options exercisable as at December 31, 2024 was 7,805,000 (December 31, 2023 - 6,680,000). The weighted average life remaining for the outstanding options were 4.1 years and weighted average exercise price was \$0.32 per option.

Restricted Stock Units

During the year ended December 31, 2022, the Company granted an aggregate of 3,275,000 restricted stock units (the "RSU") to officers, directors, key employees and consultants pursuant to the Company's RSU Plan with a fair value of \$0.05 per RSU. The RSU will be vested 1/3 on the 12, 24 and 36 months' anniversary. These units are exercisable until October 15, 2026.

The fair value of RSUs awarded to officers, directors, key employees and consultants was estimated on the dates of award using the fair market value of the Company share price. As of September 30, 2025, the Company has 3,275,000 RSUs issued and outstanding; and 2,183,333 RSUs exercisable.

In January 2025, Directors, Management and Consultants to the Company converted 2,023,500 Restricted Share Units (RSU) that vested into Subordinated Voting Shares (SVS) of which 1,923,500 were issued to Related Parties.

11. WARRANTS

In connection with private placements closed during the year 2023, the Company issued 13,093,488 non-transferable warrants. Each warrant entitles the holder thereof to purchase one additional subordinate voting share of the Company at a price of \$C0.15 per share for a period of 24 months from the closing date. The fair value of warrants was valued using the Black-Scholes Option Pricing Model.

In connection with private placements closed during the year 2024, the Company issued 61,801,421 non-transferable warrants. Each warrant entitles the holder thereof to purchase one additional subordinate voting share of the Company at an average price of \$C0.16 per share for a period of 24 months from the closing date. The fair value of warrants was valued using the Black-Scholes Option Pricing Model.

The warrants outstanding and exercisable as at September 30, 2025 are as follows:

	Expiry Date	Number of warrants outstanding	Number of warrants exercisable	Exercise Price (\$)
Balance, December 31, 2022		48,179,316	48,179,316	0.29
Granted	October 26, 2025	5,524,398	5,524,398	0.37
Expired	January 28, 2023	(182,000)	(182,000)	0.37
Balance, December 31, 2023		53,421,714	47,997,316	0.26
Expired	November 9, 2024	(42,354,070)	(42,354,070)	0.37
Granted	October 19, 2025	3,788,587	3,788,587	0.11
Granted	December 22, 2025	1,400,451	1,400,451	0.11
Granted	June 2, 2025	7,904,450	7,904,450	0.11
Granted	April 18, 2026	50,454,544	50,454,544	0.09

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

Granted	July 26, 2026	11,346,877	11,346,877	0.16
Balance, December 31, 2024		85,727,193	86,062,553	0.11
Expired	January 28, 2025	(5,307,894)	(5,307,894)	0.37
Expired	June 2, 2025	(7,904,450)	(7,904,450)	0.11
Balance, September 30, 2025		72,514,849	72,514,849	0.11

12. WARRANT LIABILITY

The Company's warrant liability arises as a result of the issuance of warrants exercisable in Canadian dollars ("CAD"). As the denomination currency of the exercise price is different from the US dollar functional currency of the entity issuing the underlying warrants, the Company recognizes a derivative liability for these warrants and re-measures the liability at the end of each reporting period using the BlackScholes model. Changes in respect of the Company's warrant liability are as follows:

	Sep 30, 2025	Dec 31, 2024
	\$	\$
Balance at beginning of the period	1,583,842	492,982
Additions	-	2,181,719
Fair value adjustments	(414,007)	(1,090,859)
Exercise of warrants	-	-
Others		
	1,169,835	1,583,842

Valuation of the warrant liability requires the use of highly subjective estimates and assumptions including the expected stock price volatility. The expected volatility used in valuing warrants is based on volatility observed in historical periods and comparative companies' historical information. Changes in the underlying assumptions can materially affect the fair value estimates. The fair value of the warrant liability was calculated using the Black-Scholes model with the following weighted average assumptions and resulting fair values:

	Sep 30, 2025 \$	Dec 31, 2024	
		\$	
Risk-free interest rate	3.09%	2.90%	
Expected dividend yield	0%	0%	
Expected warrant life (years)	1.40	1.80	
Estimated stock price volatility	131%	131%	
Fair value	\$ 0.17	\$ 0.18	

13. RELATED PARTY TRANSACTIONS

The aggregate value of transactions recorded relating to key management personnel and entities which they have control or significant influence were as follows (except the reversals mentioned in note 14):

		For the quarter ended	For the quarter ended
Related Party	Notes	Sep 30, 2025	Jun 30, 2025
		\$	\$
EMulate Therapeutics Inc. – Royalty Fees	(a)	-	9,484
Les Consultants Shtern Inc.	(b)	-	75,000
4114566 Canada Inc.	(c)	-	15,000
David Hoppenheim	(d)	-	24,000
Brian Mogen	(e)	-	45,000
Alchemy Global	(f)	-	30,000

a) EMulate Therapeutics Inc., an entity that has significant influence on Hapbee charged royalty fees. These royalty fees are calculated on a quarterly basis and are based on a percentage of profits from device sales and a percentage of subscription revenues net of platform fees.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

- **b)** Les Consultants Shtern Inc., an entity owned by then Hapbee's Chief Executive Officer Yona Shtern, charged management consulting fees to Hapbee for CEO services rendered.
- c) 4114566 Canada Inc., an entity controlled by Hapbee's Corporate Secretary Kenneth Adessky, charged management consulting fees to Hapbee for services rendered.
- d) David Hoppenheim was the Chief Operating Officer (COO) of Hapbee and charged management consulting fees for COO services rendered.
- e) Brian Mogen was the Chief Technology Officer (CTO) of Hapbee and was paid a fixed salary for CTO services rendered.
- **f)** Alchemy Global is an entity controlled by the Company's Chairman Rizwan Shah, charged management consulting fees to the Company for services rendered.

The following table outlines Hapbee's related party payables (see nature of relationship to Company above):

	Sep 30, 2025	Dec 31, 2024
	\$	\$
Les Consultants Shtern (Yona Shtern, CEO)	-	248,196
MK & Associates	-	135,358
4114589 Canada Inc. (Kenneth Adessky, Corporate Secretary)	-	186,906
EMulate Therapeutics Inc.	-	489,388
David Hoppenheim (COO)	-	149,787
Brian Mogen (CTO)		185,600
Total		1,395,235

14. PROMISSORY NOTES

Several of the Company's consultants and employees agreed to defer collection of the outstanding portion of their fees for services and salaries as at April 30, 2023 by issuing a Promissory Note, details as follows:

The Company adopted a phased in approach to base compensation whereas deferred compensation be phased in as per: phase 1 - November 2022 to April 2023 (inclusive) be deferred, phase 2 - as of May 1, 2023 (assuming equity raise) be paid 50% of base salary. Phase 3 - as of September 1, 2023 (assuming equity raise) be paid 100% of base salary. A 3-year note was assigned to employees to compensate them for their deferred compensation. Terms of the note and repayment are as follows:

Period: 3 year note with a maximum amount of US\$1.5 million

Repayment in 3 annual payments with the first third, payable on the closing of a US\$3 million financing by January 1, 2024; second third payable 12 months after first repayment or earlier at the discretion of the Board of Directors; final third payable

12 months after second repayment or earlier at the discretion of the Board of Directors. The Company has discretion to repay amounts at an earlier date on approval of the Board of Directors. Interest in the form of equity converted to RSU's at \$0.10/share; pro-rated to the number of months outstanding when repaid and payable at 50% of the deferred amounts per employee.

In Q3 2025, several of the employees who were eligible for deferred compensation agreed to waive their rights to the same due to the company's current financial situation. After the said adjustments, the promissory notes are valued at USD 351,335 as of 30th September 2025.

With relation to the above, waiver of deferred compensation/promissory notes, the company has reversed \$147,800 from salaries and wages, balance after reversal being (\$127,230) and \$1,670,236 from consulting expenses, balance after reversal being (\$1,427,007).

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

15. CONVERTIBLE DEBENTURE

The company received 2 loans of \$25,000USD each from two (2) directors on February 14, 2024, for a term of 3 years with interest payable at fifteen (15%) per annum by issuance of convertible debentures. The loans include one subordinated voting share purchase warrant (each, a "Warrant") for every eleven cents (\$0.11CAD) of principal amount of debentures subscribed for being, with each warrant exercisable at a price of \$0.11CAD to purchase one (1) common share for a period of 36 months from the date of issuance.

The debentures are convertible at the holder's option into fully-paid and non-assessable shares at any time prior to the last business day immediately preceding the maturity date for redemption by the company at a conversion price of the lower of \$0.055 per share or the most recent price of a financing close (the "Conversion Price").

The company received a loan of \$150,000CAD from an unrelated party on February 14, 2024, for a term of 3 years with interest payable at fifteen (15%) per annum by issuance of convertible debentures. The loan includes one subordinated voting share purchase warrant (each, a "Warrant") for every eleven cents (\$0.11CAD) of principal amount of Debentures subscribed for being, with each Warrant exercisable at a price of \$0.11CAD to purchase one (1) Common Share for a period of 36 months from the date of issuance. The debentures are convertible at the holder's option into fully-paid and non-assessable Shares at any time prior to the last business day immediately preceding the maturity date for redemption by the Company at a conversion price of the lower of \$0.055CAD per share or the most recent price of a financing close (the "Conversion Price").

16. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other shareholders. The Company considers the items included in shareholders' equity as capital. The Company manages the capital structure and makes adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets. The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through equity or debt financing. The Company is not subject to any externally imposed capital requirements. There were no changes in the Company's approach to capital management.

17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments consist of cash and accounts payable. The fair values of the Company's cash and accounts payable approximate their carrying values, due to their short-term natures. The Company's cash is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities. The Company's financial instruments are exposed to certain financial risks, including currency risk, credit risk, liquidity risk, interest rate risk and price risk.

Credit risk

Credit risk is the risk of loss due to the counterparty's inability to meet its obligations. The Company's exposure to credit risk is on its cash. Risk associated with cash is managed through the use of major banks which are high credit quality financial institutions as determined by rating agencies. Credit risk is assessed as low.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulties in meeting obligations when they become due. The Company aims to ensure that there is sufficient capital in order to meet short-term operating requirements, after taking into account the Company's holdings of cash. The Company believes that the capital sources will be sufficient to cover the expected cash requirements by obtaining financing through the issuance of debt or common shares. Liquidity risk is assessed as high.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates.

Notes to the Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and 2024

a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not currently exposed to interest rate risk.

b) Price risk

The Company is exposed to price risk with respect to equity prices. Equity price risk is defined as the potentially adverse impact on the Company's ability to obtain equity financing due to movements in individual equity prices or general movements in the level of the stock market. The Company is not exposed to price risk as it has no instruments in publicly held securities.

c) Foreign currency risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.

18. COMMITMENTS AND CONTINGENCIES

a) On July 29, 2021, the Company entered into an exclusive license agreement with Emulate. The agreement will be in effect for 20 years. Based on the agreement, the Company will obtain from EMulate certain exclusive rights and licenses to develop, use, import, and commercialize consumer digital products using EMulate's technology. In exchange, the Company will pay EMulate an upfront non-refundable, non-creditable payment of \$10,000 for the cognate designated by and provided to the Company. The Company will also pay to EMulate royalties on the quarterly new income from sales, lease or rental of the authorized product in the territory multiplied by a percentage royalty rate of 20%. During the quarter ended March 31, 2025, the royalty fees paid to Emulate of \$489,388 was paid by way of conversion of the debt into 10,500,000 subordinated voting (December 31, 2024—\$489,388).

The company is currently in discussion with Emulate regarding certain amounts that were recognized and paid for in the earlier years. Accordingly, the company has not recognized any royalties as payable to Emulate in Q3 2025 pending the resolution of the matter.

b) The Company has entered into a supply agreement with its supplier and committed to purchasing 25,000 units of its primary product with an estimated cost of \$2,500,000.